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SUMMARY 
 
Hidradenitis suppurativa (HS) is an inflammatory skin disease with poorly understood 
immunopathogenic mechanisms. LL-37 is an antimicrobial peptide, which is transcribed from 
the CAMP (cathelicidin antimicrobial peptide) gene. Previous reports showed upregulated 
levels of CAMP and LL-37 in HS lesions and therefore the aim of this study was to compare 
levels of LL-37 in HS to other inflammatory skin diseases and to establish 
immunomodulatory functions of LL-37 in HS. We confirm an upregulation of the LL-37 
peptide in lesional HS skin with comparable levels as in psoriasis patients and are able to 
positively correlate the presence of LL-37 in HS with the presence of T cells, macrophages, 
neutrophils, IFNγ, IL-17, IL-23, TNFα, IL-32 and IL-1β. Mechanistically, LL-37 boosts the 
proliferation of unspecifically activated CD4+ T cells via an increased calcium signalling 
independent of antigen presenting cells. Targeting LL-37 may therefore represent a new 
therapeutic option for the treatment of this recalcitrant disease, but it has to be kept in mind 
that LL-37 also has an antimicrobial function.  
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INTRODUCTION  
Hidradenitis suppurativa (HS), also termed acne inversa, is a chronic inflammatory disease 
of the apocrine gland-bearing skin. HS lowers the quality of life of affected patients to a 
higher degree than other inflammatory skin diseases and is characterised by painful 
subcutaneous nodules in the axillary, inguinal and anogenital regions of the body.1, 2 These 
nodules can progress into deep dermal abscesses with sinuses and fistula, accompanied by 
malodorous suppuration.2 Efficient therapy of this recalcitrant disease is highly challenging 
due to the poor understanding of the involved pathogenetic mechanisms. Nowadays, the 
trigger for HS is thought to be hyperkeratinisation of the hair follicle, which leads to distention 
and rupture of the pilosebaceous unit, leading to an infiltration of inflammatory cells with a 
subsequent dysregulation of the immune system.3, 4  
LL-37 is the only mature human antimicrobial peptide (AMP) of the cathelicidin family and is 
transcribed and processed from the CAMP gene. It has an alpha-helical and amphipathic 
structure, which enables LL-37 to kill bacteria.5, 6 LL-37 is produced by activated tissue 
resident cells such as keratinocytes and epithelial cells (ECs), but also by innate and 
adaptive immune cells, such as neutrophils, macrophages, T cells and B cells.7-13 Next to its 
antimicrobial function, LL-37 is also a potent immunoregulator. LL-37 is a chemoattractant for 
CD4+ T cells10 and, in vitro LL-37-stimulated dendritic cells upregulate co-stimulatory 
molecules and increase the production of TNFα, IL-6 and IL-12, which leads to the induction 
of a Th1/Th17 phenotype in T cells.14-16 Moreover, in human peripheral blood mononuclear 
cells (PBMCs), LL-37 enhances certain pro-inflammatory responses in synergy with IL-1β, 
such as an increased production of CCL2, CCL7, CXCL-8 and IL-6.17 Furthermore, LL-37 
has an impact on cell proliferation in angiogenesis and wound healing, and regulates hair 
growth.18-20 LL-37 also promotes the establishment of several chronic inflammatory diseases 
such as obesity, insulin resistance and atherosclerosis.21, 22 In PS, LL-37 is upregulated and 
some patients even possess autoreactive skin-homing T cells which can recognize LL-37. 9, 
23 In contrast to psoriasis (PS) patients, atopic dermatitis (AD) patients have decreased 
serum levels of LL-37.24 These low levels could be attributed to high IL-10 levels, which 
suppress the induction of LL-37.25 In HS, elevated CAMP and LL-37 levels have been 
reported,26, 27 which were found to be produced by ECs around inflamed hair follicles in the 
outer root sheath and in the adjacent apocrine sweat glands.27  
Due to these results in the literature, we sought to further delineate the role of LL-37 in HS by 
comparing its levels to other inflammatory skin diseases and by deepening the 
understanding of the immunomodulatory function of LL-37 in HS. To this end, we 
investigated the expression of LL-37 and CAMP in HS, PS, AD and healthy skin by 
immunohistochemistry and semi-quantitative real time PCR and compared whether LL-37 
peptide and CAMP mRNA levels correlate in lesional HS skin. In addition, we examined what 
4 
 
4 
 
kind of cells (T cells, macrophages, and neutrophils) and cytokines (IFNγ, IL-17, IL-23, IL-32, 
IL-1β, TNFα and IL-10), which are known to be elevated in HS28-35 correlate with the 
presence of LL-37. To complete our analysis, we investigated the impact of LL-37 on the 
proliferation of lectin stimulated CD4+ and CD8+ T cells isolated from the blood of healthy 
donors and HS patients and delineated by calcium assay, how LL-37 impacts proliferation of 
T cells directly. 
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MATERIAL AND METHODS 
Samples from patients 
The design of this study followed the Declaration of Helsinki protocols and was approved by 
the Medical Ethics Committee of the Canton of Berne, Switzerland. Before enrolment, all 
study subjects signed a written informed consent. Skin biopsies were obtained from 24 HS 
patients (median age 36.5 years, range 21-51 years, mean Hurley stage 2.25±0.68). 
Furthermore, skin biopsies from 5 PS patients (median age 54 years, range 33-59 years) and 
5 AD patients (median age 25 years, range 18-48 years) were collected. Biopsies were 
targeted in the central lesional area. Healthy control skin was obtained from intertriginous 
skin areas of 9 donors (median age 41 years, range 23-66 years). Skin samples were 
immediately embedded in optimal cutting temperature (OCT) compound (Sakura Finetek, 
USA), snap frozen with liquid nitrogen and stored at -70°C. PBMCs were isolated by Ficoll 
density gradient centrifugation from 14 HS patients (median age 33 years, range 18-64 
years) and 15 healthy controls (median age 33.5 years, range 23-74 years). After isolation, 
PBMCs were immediately frozen and stored at -80°C in fetal calf serum (FCS) (Biochrom, 
Berlin, Germany) + 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, USA). 
Immunohistochemical staining 
Immunostaining was performed as previously described.28 In brief, air dried cryostat-cut 
tissue sections were fixed in 4% cold acetone (10 minutes) and rehydrated in 0.1% saponin 
containing TRIS buffered saline. After 15 minutes blocking (Roti-ImmunoBlock, Roth GmbH, 
Karlsruhe, Germany), the sections were incubated at room temperature with the primary 
antibody (rabbit-anti-human LL-37 [Abcam, Cambridge, UK], mouse-anti-human CD3 
[Biolegend, San Diego, USA], mouse-anti-human CD66b [Biolegend] or mouse-anti-human 
CD68 [Dako, Santa Clara, USA]) for one hour. This was followed by a one hour incubation 
with a biotinylated swine-anti-rabbit or rabbit-anti-mouse antibody (Dako) and thereafter with 
the streptavidin-biotin complex/alkaline phosphatase method (BD Biosciences, San Diego, 
USA; Dako). Finally, a three minutes counterstaining with hematoxylin was performed. As a 
negative control, the tissue was only stained with the secondary antibody. To determine the 
score for the presence of LL-37, CD3, CD66b and CD68 sections were analysed for stained 
cell density and cell distribution across the biopsy. The allocation of a semi-quantitative score 
was attributed as previously described,36 using the following scale (in steps of 0.5): 0 = 
absent, 1 = weak/low expression with little distribution, 2 = moderate expression with 
intermediate distribution, 3 = strong expression with wide distribution. 
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RNA isolation, complementary DNA synthesis and semi-quantitative real-time PCR 
analysis 
As previously described,28 OCT-embedded biopsies were cut into 10µm sections, before the 
RNA was extracted with the help of the RNeasy lipid tissue mini kit (Qiagen, Valencia, USA). 
A RNase-free DNase step removed contaminating DNA (Qiagen). Complementary DNA was 
then synthesised utilising the BD Reverse Transcriptase Kit (BD Biosciences). For semi-
quantitative real-time PCR pre-made Taqman© gene expression assays were used with 
exon-exon spanning primers and probes (Applied Biosystems, Foster City, USA); target 
genes: CAMP (Hs00189038_m1), IFNγ (Hs00174143_m1), IL-17 (Hs00174383_m1), IL-23 
(Hs00372324_m1), IL-1β (Hs01555410_m1), TNFα (Hs00174128_m1), IL-10 
(Hs00174086_m1) and IL-32 (Hs00992441_m1); reference genes: β2-microglobulin (B2M) 
(Hs99999907_m1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
(Hs99999905_m1) and hypoxanthine phosphoribosyltransferase-1 (HPRT-1), 
(Hs99999909_m1). The PCR was performed on an ABI-Prism 7300 Sequence Detector 
System (Applied Biosystems) as described in Ref.28 The final results are expressed as fold 
differences. These differences were calculated with the 2-ΔΔCT method. The threshold cycle 
(CT) for the reference genes was determined by using the geometric mean of the CT of the 
three reference genes, see Ref.37 In samples where no CT-value was detected, CT-value 
was set to 40, as previously described.38 
Proliferation assay 
PBMCs from healthy donors and HS patients were stained with 0.7µM Carboxyfluorescein 
succinimidyl ester (CFSE) for five minutes. Then PBMCs were plated in 96 round-bottom well 
plates in R9 medium (RPMI 1640 [Life Technologies, Basel, Switzerland], 2mM L-glutamine 
[Biochrom, Berlin, Germany], 50U/mL penicillin, 50µg/ml streptomycin [Bioconcept, Allschwil, 
Switzerland], 5% heat-inactivated human AB serum [Swiss Red Cross, Bern, Switzerland]) 
with 1µg/mL phytohaemagglutinin (PHA, [Brunschwig Chemie, Basel, Switzerland]) and three 
different concentrations of LL-37 (AnaSpec, Freemont, USA) (2µg/ml, 10µg/mL and 
30µg/mL) and 30µg/mL of a scrambled control peptide LL-37 (Innovagen, Lund, Sweden). 
Flow cytometry analysis (FACS canto, BD biosciences) was performed after three days in 
culture with the following staining: CFSE (FITC), CD3 (PE-Cy7), CD4 (APC-Cy7) and CD8 
(APC) (all biolegend). For analysis of T cells only, PBMCs were sorted via magnetic beads 
for the expression of CD3 (EasySep™ Human CD3 Positive Selection Kit (Stemcell, 
Vancouver, Canada) according to the manufacturer’s protocol, before analysis after five days 
in culture. Proliferation rates of CD4+ and CD8+ T cells, were normalised to no LL-37 
addition. 
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Calcium influx assay 
Calcium influx measurements were assessed as described previously.39 Briefly, PHA blasts, 
generated from healthy PBMCs in the presence of 50 IU/mL IL-2 (Roche, Basel, Switzerland) 
and PHA, were incubated with 2mg/ml fluo-4-AM (Invitrogen, Carlsbad, USA) and plated in 
half-area, clear-bottom, 96-well plates (VWR International, Dietikon, Switzerland) at 105 
cells/well. The data were measured on a Synergy-4 instrument (BioTek, Highland Park, USA) 
with an excitation band of 485/20nm, and fluorescence was detected at 528/20nm. A 
baseline signal (F0) was recorded for five minutes before the addition of PHA alone (2µg/ml) 
or PHA with three different concentrations of LL-37 (2µg/ml, 10µg/mL and 30µg/mL). 
Subsequently, fluorescence intensity (F) was monitored for 60 minutes. As negative control, 
PHA blasts were incubated with medium only. The results are presented as normalised 
fluorescence to the baseline level (F/F0). 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism software (version 5.01 for Windows, 
San Diego, USA). Semi-quantitative real time PCR was evaluated by means of the non-
parametric Mann-Whitney test. The non-parametric Spearman’s rank correlation coefficient 
(rS) was used to statistically analyse correlations. The statistical significance of the 
proliferation assays were assessed with the non-parametric paired Wilcoxon signed rank 
test. A p-value less than 0.05 was considered statistically significant; p<0.05 = *, p<0.01 = **, 
p<0.001= ***.  
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RESULTS 
LL-37 peptide is expressed in lesional HS skin 
LL-37 expression was immunohistochemically analysed on tissue sections of lesional HS 
skin. As comparison, lesional skin from AD and PS patients and healthy skin was assessed. 
Figure 1a-d shows representative examples of LL-37 staining in cryo-cut tissues and the 
semi-quantitative analysis of these stainings is presented in Figure 1e. Whereas lesional HS 
skin showed a dense infiltration of LL-37+ cells in highly inflamed dermal areas and weak 
expression by keratinocytes, without any accumulation around the hair follicle, the dermal 
distribution of LL-37+ cells is more uniform and brighter in the epidermis in PS lesions. In AD, 
occurrence of LL-37+ cells is sparse and comparable to healthy skin. Examining the 
morphology of clearly positive LL-37+ cells in lesional HS skin, we suggest that LL-37 is 
present in granulocytes, which was underlined with a positive double staining for neutrophils 
(data not shown).  
 
In HS, CAMP mRNA levels do not always correspond to LL-37 peptide levels 
After determining that LL-37 expression was increased in lesional HS skin, we sought to 
investigate whether these peptide levels correspond with the CAMP mRNA expression. 
Therefore, we used semi-quantitative RT-PCR to quantify relative changes of CAMP mRNA 
in lesional HS, PS, AD and healthy skin (Fig. 2a). In accordance with our IHC results, PS 
skin showed an upregulated presence of CAMP, while in AD no difference in mRNA 
presence compared to healthy skin could be demonstrated. In HS, a mean four times 
increase was observed, however, due to wide-spread individual sample values, this 
difference was not statistically significant compared to healthy skin. While some HS biopsies 
showed a clear increase in CAMP levels, others showed similar expression as in healthy skin 
or even a decreased presence of CAMP mRNA. This led us to the question, whether in HS 
LL-37 is transcribed and translated locally or partly also elsewhere. To this aim we correlated 
the semi-quantitative peptide score with the results of the CAMP mRNA analysis. This 
analysis (Fig. 2b) showed a non-significant correlation of the peptide and mRNA levels in 
lesional HS skin. 
 
Positive correlation of LL-37 peptide presence with lesional inflammatory status 
Next, we assessed the potential pathogenic role of LL-37 in HS by investigating both the 
correlation of LL-37 peptide levels with lesional parameters of disease severity, as well as 
with other pro- and also anti-inflammatory cytokines (IFNγ, IL-17, IL-23, IL-1β, TNFα, IL-32 
and IL-10). Our data demonstrates that LL-37 peptide levels in lesional HS skin positively 
correlate with the presence of T cells, macrophages and neutrophils (Suppl. Fig. 1a-c). 
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Interestingly, the cytokines mentioned above also positively correlated with LL-37 levels (Fig. 
3a-d, Suppl. Fig. 1d-f). 
 
LL-37 drives the proliferation of T cells in the presence of an unspecific activation 
independent of antigen presenting cells via an increased calcium influx 
To investigate the immunomodulatory role of LL-37 in HS patients, we focused on the impact 
of LL-37 on the proliferation of both CD4+ and CD8+ T cells. For this reason, PBMCs from 
healthy donors and HS patients were stained with CFSE and incubated for three days with 
PHA, a lectin, which leads to a polyclonal activation of T cells, and increasing concentrations 
of LL-37. In the presence of PHA, we report that LL-37 increases the proliferation rate of T 
cells, in particular of CD4+ T cells (Fig. 4a-b). To determine whether the observed increased 
proliferation is due to a LL-37 mediated maturation of antigen presenting cells (APCs), we 
analysed magnetically purified CD3+ T cells. After an incubation time of five days, similar, if a 
bit more pronounced, pro-proliferative effects of LL-37 on CD4+ T cells in the presence of 
PHA were observed (Fig 4c-d). We could conclude that the proliferation enhancement was a 
direct effect of LL-37 on stimulated T cells. To figure out how this effect is mediated, we 
measured the calcium influx in PHA blasts, which were stimulated with PHA alone or with 
PHA in the presence of increasing concentrations of LL-37 (Fig. 4e). Indeed, we were able to 
detect a more prominent increase of the calcium influx in the presence of PHA and LL-37 
compared to PHA only.  
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DISCUSSION 
Here we show that LL-37 is upregulated on the peptide level in skin lesions of patients 
suffering from the recalcitrant skin disease HS, as already indicated by Emelianov et al.27 On 
the CAMP mRNA level, we report an upregulation in PS, while no differences to healthy skin 
could be detected in AD skin. In HS, we cannot completely confirm Bechara et al.’s mRNA 
results,26 as we only describe a mean four times increase in HS compared to healthy skin, 
but do not detect any statistically significant upregulation. By correlating peptide and mRNA 
levels, we were able to determine that LL-37 and CAMP do not correspond in all HS 
biopsies. This suggests that in some HS lesions LL-37 is either not produced locally and 
enters HS dermis in pre-stored granuli or CAMP mRNA is quickly degraded or translated 
after transcription. This might, on the one hand, explain the vast range of CAMP mRNA 
levels detected in HS lesions and, on the other hand, resolve the discrepancy between the 
peptide and mRNA levels found in HS biopsies.  
LL-37 levels in lesional HS skin positively correlate with the presence of T cells, 
macrophages and neutrophils, as well as with the pro-inflammatory IFNγ, IL-17, IL-23, IL-1β, 
TNFα and IL-32 and also with the anti-inflammatory IL-10, which suggests that LL-37 
correlates with the establishment of a Th1/Th17 phenotype and other pro-inflammatory loops  
in lesional HS skin. Moreover, we report that in the presence of PHA, LL-37 drives CD4+ T 
cell proliferation independent of APC help. However, in contrast to PS patients, as it was 
described by Lande et al.,23 we never detected any proliferation of T cells from HS patients in 
the presence of LL-37 alone (Suppl. Fig. 2). The proliferative effect was found to be mediated 
by an additional influx of calcium into the T cells after a co-stimulation with PHA and LL-37. 
Interestingly, the calcium influx after PHA+LL-37 starts earlier than with PHA alone, 
suggesting that LL-37 mediates its effect directly via the membrane and is not receptor 
mediated, which has already been a suggested mechanism in the literature.40 The question 
why LL-37 has a more prominent impact on the proliferation of CD4+ T cells remains. It was 
reported that LL-37 induces apoptosis in stimulated mouse CD8+ T cells, which could 
counter-regulate this pro-proliferative effect.41 
Concerning the role of LL-37 in HS pathogenesis, we hypothesise that LL-37 is present in 
early lesions, but then also remains high in the chronic phase, becoming a driver of the pro-
inflammatory cascade. The arguments in favour of this hypothesis are that LL-37 is mainly 
produced by neutrophils, which enter the lesional skin early after initiation of inflammation 
where LL-37 mainly exerts its antimicrobial function. What is more, the presence of LL-37 
also coincides with T cells and macrophages which enter HS lesions at a later stage and 
under the influence of LL-37 and other mediators, they may start producing Th1/Th17 
cytokines, further driving the pro-inflammatory process.42  
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Taken together, we report that LL-37 is upregulated in HS patients and that its presence 
correlates with other pro-inflammatory mediators, such as Th1/Th17 cytokines. Further 
investigation of the involvement of LL-37 in immunomodulation showed that LL-37 and an 
unspecific activation lead to an APC independent boost of the proliferation of CD4+ T cells 
via direct calcium signalling. More insight is needed to understand pathological mechanisms 
in HS and to understand the role of LL-37 in this process, which could pave the way for 
future treatment possibilities by blocking LL-37 in this recalcitrant skin disease.  
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FIGURES 
 
 
Figure 1 
LL-37 is highly expressed on the peptide level in lesional hidradenitis suppurativa skin 
a-d) Representative examples of frozen epidermal (above) or dermal (below) skin sections 
immunohistochemically stained for LL-37 in healthy skin and lesional skin of different 
inflammatory skin diseases (HS, PS, AD). The third HS picture represents a staining of LL-37 
around the hair follicle. Sections were counterstained with hematoxylin; 200x magnification, 
scale bars indicate 50µm. e) Quantification of the density of LL-37+ cells in the four donor 
groups. Score ranges from 0–3. n(healthy skin) = 5, n(HS) = 24, n(PS) = 5, n(AD) = 5. Data 
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are presented as mean with SEM and were statistically analysed with the Mann-Whitney test, 
with * indicating a p-value <0.05. 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Messenger RNA levels of CAMP in hidradenitis suppurativa are not statistically 
elevated and do not correlate with LL-37 peptide levels  
a) Analysis of CAMP mRNA expression in lesional HS skin normalised to healthy skin and 
compared to lesional PS and AD skin. Ct-values were normalised with housekeeping genes 
HPRT-1, GAPDH and B2M to healthy skin (=1); n(healthy skin)=9, n(HS)=24, n(PS)=5, 
n(AD)=5. Data are presented as mean with SEM and were statistically analysed with the 
Mann Whitney test with ** indicating a p-value <0.01. b) Correlation of LL-37 peptide levels 
with CAMP mRNA levels in lesional HS skin (rS= 0.28). n(HS)=24. Significance of correlation 
was determined with the Spearman’s rank correlation coefficient (rS). 
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Figure 3 
Peptide levels of LL-37 in hidradenitis suppurativa skin positively correlate with 
Th1/Th17 associated cytokines 
a-d) LL-37 levels positively correlate with mRNA levels of the Th1/Th17 associated cytokines 
IFNγ (rS=0.70), IL-17 (rS=0.66), IL-23 (rS= 0.70) and IL-1β (rS= 0.68). Ct-values of mRNA 
analysis were normalised with housekeeping genes HPRT-1, GAPDH and B2M to healthy 
skin (=1); n(HS)=24. Significance of correlation was determined with the Spearman’s rank 
correlation coefficient (rS) with* indicating a p-value <0.05, ** indicating a p-value <0.01 and 
*** indicating a p-value <0.001.  
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Figure 4 
LL-37 together with an unspecific activation increases the proliferation of T cells by 
increasing the calcium influx independent of antigen presenting cells  
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a-b) Normalised proliferation ratios of CD4+ and CD8+ T cells in healthy donors and HS 
patients, which were incubated in a PBMC pool of cells in the presence of PHA and different 
concentrations of LL-37 and a scrambled control peptide. c-d) Normalised proliferation ratios 
of CD4+ and CD8+ T cells in healthy donors and HS patients, which were incubated in a pure 
T cell culture in the presence of PHA and different concentrations of LL-37 and a scrambled 
control peptide. Data of the proliferation of T cells are normalised to the percentage of CFSE 
low cells without LL-37 addition. Results are presented as mean with SEM and were 
statistically analysed with the non-parametric Wilcoxon rank sum test with * indicating a p-
value <0.05 and ** indicating a p-value <0.01. PBMCs: n(healthy)= 9, n(HS)=10; T cells: 
n(healthy)= 10, n(HS)=11. e) A representative example of a calcium assay with PHA blasts 
derived from a healthy donor. Fluorescence intensity is normalised to baseline levels and 
was measured for one hour. Lines indicate relative fluorescence levels in the presence of 
medium (black), PHA (blue) and PHA and increasing concentrations of LL-37 (yellow, 
orange, red). 
 
Supplementary Figure 1 
Peptide levels of LL-37 in hidradenitis suppurativa skin positively correlate with 
lesional inflammatory status and mRNA levels of pro-inflammatory mediators 
a-c) LL-37 expression positively correlates with the number of T cells (rS= 0.72), 
macrophages (rS= 0.68) and neutrophils (rS= 0.86) in lesional HS skin. d&f) LL-37 levels also 
correlate with the presence of the mRNA of pro-inflammatory mediators TNFα (rS= 0.55) and 
IL-32 (rS= 0.48). e) mRNA expression of the anti-inflammatory IL-10 positively correlates with 
LL-37 peptide levels (rS= 0.51). Ct-values of mRNA analysis were normalised with 
housekeeping genes HPRT-1, GAPDH and B2M to healthy skin (=1); n(HS)=24. Significance 
of correlation was determined with the Spearman’s rank correlation coefficient (rS) with* 
indicating a p-value <0.05, ** indicating a p-value <0.01 and *** indicating a p-value <0.001.  
 
Supplementary Figure 2 
LL-37 alone does not induce proliferation in T cells isolated from the blood of HS 
patients 
Representative example of the proliferation of T cells in an HS patients after the incubation of 
three days with LL-37 alone.  
 
 
 
